WCLC 2025 - Posters & ePosters-P3.18.78 A Prospective Study of Lurbinectedin Plusivonescimab Assecond-Line Treatment for Extensive-Stage Small Cell Lung Cancer

P3.18.78 A Prospective Study of Lurbinectedin Plusivonescimab Assecond-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Asset Subtitle

Fei Zhou

Meta Tag

Speaker Fei Zhou

Topic Clinical Trials in Progress